Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates

ABSTRACT

Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, as well as key intermediates useful in those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses

RELATED APPLICATION DATA

This application relates to U.S. Provisional Patent Application Ser. No.60/150,358, filed on Aug. 24, 1999.

This application also relates to U.S. Provisional Patent ApplicationSer. No. 60/150,365, also filed Aug. 24, 1999, entitled “EfficientMethods For The Preparation Of Rhinovirus Protease Inhibitors, KeyIntermediates And A Continuous Membrane Reactor Useful For ThePreparation Of The Same” having named as inventors: J. Tao, S. Babu, R.Dagnino, Jr., Q. Tian, T. Remarchuk, K. McGee, N. Nayyar, and T. Moran.The aforementioned application also relates to synthetic routes for thepreparation of rhinovirus protease inhibitors, as well as keyintermediates useful in their preparation. The above-mentionedapplications are relied upon and incorporated herein by reference.

TECHNICAL FIELD AND INDUSTRIAL APPLICABILITY OF INVENTION

The present invention relates to an improved process for the preparationofethyl-3-{(5′-methylisoxazole-3′-carbonyl)-L-ValΨ(COCH₂)-L-(4-F-Phe)-L-((S)-Pyrrol-Ala)}-E-propanoate,(also referred to as AG7088), its analogs and of pharmaceuticallyacceptable salts thereof. The present invention also includes a novelgroup of key intermediate compounds to be used in the above process.

BACKGROUND OF THE INVENTION

Picornaviruses are a family of tiny non-enveloped positive-strandedRNA-containing viruses that infect humans and other animals. Theseviruses include the human rhinoviruses, human polioviruses, humancoxsackieviruses, human echoviruses, human and bovine enteroviruses,encephalomyocarditis viruses, meningitis viruses, foot and mouthviruses, hepatitis A virus, and others. The human rhinoviruses are amajor cause of the common cold.

Proteolytic 3C enzymes are required for the natural maturation of thepicornaviruses. Thus, inhibiting the activity of these proteolytic 3Cenzymes should represent an important and useful approach for thetreatment and cure of viral infections of this nature, including thecommon cold.

Some small-molecule inhibitors of the enzymatic activity of picornaviral3C protease (i.e., antipicornaviral compounds) have been recentlydiscovered. See, for example: U.S. patent application Ser. No.08/850,398, filed May 2, 1997, by Webber et al.; U.S. patent applicationSer. No. 08/991,282, filed Dec. 16, 1997, by Dragovich et al.; and U.S.patent application Ser. No. 08/991,739, filed Dec. 16, 1997, by Webberet al. These U.S. patent applications, the disclosures of which areincorporated herein by reference, describe certain antipicornaviralcompounds and methods for their synthesis.

More recently, an especially potent group of antipicornaviral agentshave been discovered as set forth in U.S. patent application Ser. No.60/098,354, (the '354 application) filed Aug. 28, 1998, by Dragovich etal., which is herein incorporated by reference. This applicationdiscloses, inter alias, a group of antipicornaviral agents of generalformula I. A particularly promising compound, AG7088, falling within thescope of this group, exhibits excellent antiviral properties against aplethora of Rhinoviral serotypes and is currently in human clinicaltrials. The '354 application also discloses methods and intermediatesuseful for synthesizing these compounds. For example, General Method Vtherein discloses a general method for synthesizing the compounds offormula I involving subjecting a carboxylic acid of general formula BBto an amide-forming reaction with an amine of general formula P toprovide a final product CC, as shown below.

The '354 application further discloses methods for synthesizing theintermediates of general formulae BB and P, and teaches methods forcarrying out the amide-forming reaction referred to above. Thus, the'354 application teaches suitable methods for synthesizing the compoundsof general formula I from a carboxylic acid BB (within the scope of thecompounds of general formula II referred to below) and the compounds ofgeneral formula P (the same as the compounds of general formula IIIreferred to below.) Similarly, two recent publications by Dragovich etal. disclose antipicornavirus agents and suitable synthetic methods fortheir synthesis. See Structure-Based Design, Synthesis, and BiologicalEvaluation of Irreversable Human Rhinovirus 3C Proteases Inhibitors. 3.StructureActivity Studies of Ketomethylene-Containing Peptidonimietics,Dragovich et al., Journal of Medicinal Chemistry, ASAP, 1999; andStructure-Based Design, Synthesis, and Biological Evaluation ofIrreversable Human Rhinovirus 3C Proteases Inhibitors. 4. Incorporationof P₁ Lactam Moieties as L-Glutamine Replacements, Dragovich et al.,Journal of Medicinal Chemistry, ASAP, 1999. These aforementionedarticles are herein incorporated by reference in their entirety.

However, there is still a desire to discover improved, more efficient,processes and novel intermediates for use in the syntheses of thecompounds of the group of antipicornaviral agents. In particular, thereis a need for improved methods for synthesizing the compounds of generalformulae II and III.

SUMMARY OF THE INVENTION

The present invention relates to the discovery of a cost effective andefficient process for the preparation of the antipicornaviral agents offormula I, such as compound AG7088, as well as intermediates which areuseful in that synthesis.

The antipicornaviral agents of formula I comprise:

wherein

R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group;

R₂ and R₃ are each independently H;

where n is an integer from 0 to 5, A₁ is CH or N, A₂ and each A₃ areindependently selected from C(R₄₁)(R₄₁), N(R₄₁), S, S(O), S(O)₂,and Oand A₄ is NH or NR₄₁, where each R_(4l) is independently H or loweralkyl, provided that no more than two heteroatoms occur consecutively inthe above-depicted ring formed by A₁, A₂, (A₃)_(n), A₄ and C═O, and atleast one of R₂ and R₃ is

R₄ is

R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R₇ and R₈ are each independently H, an alkyl group, a cycloalkyl group,a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR₁₇,—SR₁₇, —NR₁₇R₁₈, —NR₁₉NR₁₇R₁₈, or —NR₁₇OR₁₈, where R₁₇, R₁₈, and R₁₉ areeach independently H, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, or an acylgroup, provided that at least one of R₇ and R₈ is an alkyl group, anaryl group, a heteroaryl group, —OR₁₇, —SR₁₇, —NR₁₇R₁₈, —NR₁₉NR₁₇R₁₈, or—NR₁₇OR₁₈; R₉ is a five-membered heterocycle having from one to threeheteroatoms selected from O, N, and S; and

Z and Z₁ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group,—C(O)R₂₁, —CO₂R₂₁, CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁,—C(S)NR₂₁R₂₂, —NO₂, —SOR₂₁, —SO₂R₂₁, —SO₂₁NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂),—SONR₂₁, —SO₃R₂₁, —PO(OR₂₁)₂ —PO(R₂₁)(R₂₂), —PO(NR_(2l)R₂₂)(OR₂₃),—PO(NR₂₁R₂₂)(NR₂₃R₂₄), —C(O)NR₂₁NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁,R₂₂, R₂₃, and R₂₄ are each independently H, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group, anacyl group, or a thioacyl group, or where any of two of R₂₁,R₂₂, R₂₃,and R₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H;

or Z₁ and R₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z₁ and R₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group;

or Z and Z₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z and Z₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group.

As discussed below, these antipicornaviral agents of formula I may besynthesized by subjecting a compound of general formula II together witha compound of general formula III to a suitable amide-forming reaction.The process of the present invention, not only reduces the number ofsteps required to synthesize the compounds of formula III, but moreimportantly, it also employs less expensive starting materials andreagents.

These objects, advantages and features of the present invention will bemore fully understood and appreciated by reference to the writtenspecification.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION

As used in the present application, the following definitions apply:

In accordance with a convention used in the art,

is used in structural formulas herein to depict the bond that is thepoint of attachment of the moiety or substituent to the core or backbonestructure.

Where chiral carbons are included in chemical structures, unless aparticular orientation is depicted, both sterioisomeric forms areintended to be encompassed.

An “alkyl group” is intended to mean a straight or branched chainmonovalent radical of saturated and/or unsaturated carbon atoms andhydrogen atoms, such as methyl (Me), ethyl (Et), propyl, isopropyl,butyl (Bu), isobutyl, t-butyl (t-Bu), ethenyl, pentenyl, butenyl,propenyl, ethynyl, butynyl, propynyl, pentynyl, hexynyl, and the like,which may be unsubstituted (i.e., containing only carbon and hydrogen)or substituted by one or more suitable sustituents as defined below(e.g., one or more halogens, such as F, Cl, Br, or I, with F and Clbeing prefered). A “lower alkyl group” is intended to mean an alkylgroup having from 1 to 4 carbon atoms in its chain.

A “cycloalkyl group” is intended to mean a non-aromatic monovalentmonocyclic, bicyclic, or tricyclic radical containing 3, 4, 5, 6, 7, 8,9, 10, 11, 12, 13, or 14 carbon ring atoms, each of which may besaturated or unsaturated, and which may be unsubstituted or substitutedby one or more suitable substituents as defined below, and to which maybe fused one or more heterocycloalkyl groups, aryl groups, or heteroarylgroups, which themselves may be unsubstituted or substituted by one ormore substituents. Illustrative examples of cycloalkyl groups includethe following moieties:

A “heterocycloalky group” is intended to mean a non-aromatic monovalentmonocyclic, bicyclic, or tricyclic radical, which is saturated orunsaturated, containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, or 18 ring atoms, which includes 1, 2, 3, 4, or 5 heteroatomsselected nitrogen, oxygen, and sulfur, where the radical isunsubstituted or substituted by one or more suitable substituents asdefined below, and to which may be fused one or more cycloalkyl groups,aryl groups, or heteroaryl groups, which themselves may be unsubstitutedor substituted by one or more suitable substituents. Illustrativeexamples of heterocycloalkyl groups include the following moieties:

An “aryl group” is intended to mean an aromatic monovalent monocyclic,bicyclic, or tricyclic radical containing 6, 10, 14 or 18 carbon ringatoms, which may be unsubstituted or substituted by one or more suitablesubstituents as defined below, and to which may be fused one or morecycloalkyl groups, heterocycloalkyl groups, or heteroaryl groups, whichthemselves may be unsubstituted or substituted by one or more suitablesubstituents. Illustrative examples of aryl groups include the followingmoieties:

A “heteroaryl group” is intended to mean an aromatic monovalentmonocyclic, bicyclic, or tricyclic radical containing 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, or 18 ring atoms, including 1, 2, 3, 4,or 5 heteroatoms selected from nitrogen, oxygen, and sulfur, which maybe unsubstituted or substituted by one or more suitable substituents asdefined below, and to which may be fused one or more cycloalkyl groups,heterocycloalkyl groups, or aryl groups, which themselves may beunsubstituted or substituted by one or more suitable substituents.Illustrative examples of heteroaryl groups include the followingmoieties:

A “heterocycle” is intended to mean a heteroaryl or heterocycloalkylgroup (each of which, as defined above, are optionally substituted).

An “acyl group” is intended to mean a —C(O)—R radical, where R is asubstituent as defined below.

A “thioacyl group” is intended to mean a —C(S)—R radical, where R is asubstituent as defined below.

A “sulfonyl group” is intended to mean a —SO₂R radical, where R is asubstituent as defined below.

A “hydroxy group” is intended to mean the radical —OH.

An “amino group” is intended to mean the radical —NH₂.

An “alkylamino group” is intended to mean the radical —NHR_(a), whereR_(a) is an alkyl group.

A “dialkylamino group” is intended to mean the radical —NR_(a)R_(b),where R_(a) and R_(b) are each independently an alkyl group.

An “alkoxy group” is intended to mean the radical —OR_(a), where R_(a)is an alkyl group. Exemplary alkoxy groups include methoxy, ethoxy,propoxy, and the like.

An “alkoxycarbonyl group” is intended to mean the radical —C(O)OR_(a),where R_(a) is an alkyl group.

An “alkylsulfonyl group” is intended to mean the radical —SO₂R_(a),where R_(a) is an alkyl group.

An “alkylaminocarbonyl group” is intended to mean the radical—C(O)NHR_(a), where R_(a) is an alkyl group.

A “dialkylaminocarbonyl group” is intended to mean the radical—C(O)NR_(a)R_(b), where R_(a) and R_(b) are each independently an alkylgroup.

A “mercapto group” is intended to mean the radical —SH.

An “alkylthio group” is intended to mean the radical —SR_(a), whereR_(a) is an alkyl group.

A “carboxy group” is intended to mean the radical —C(O)OH.

A “carbamoyl group” is intended to mean the radical —C(O)NH₂.

An “aryloxy group” is intended to mean the radical —OR_(c), where R_(c),is an aryl group.

A “heteroaryloxy group” is intended to mean the radical —OR_(d), whereR_(d) is a heteroaryl group.

An “arylthio group” is intended to mean the radical —SR_(c), where R_(c)is an aryl group.

A “heteroarylthio group” is intended to mean the radical —SR_(d), whereR_(d) is a heteroaryl group.

A “leaving group” (Lv) is intended to mean any suitable group that willbe displaced by a substitution reaction. One of ordinary skill in theart will know that any conjugate base of a strong acid can act as aleaving group. Illustrative examples of suitable leaving groups include,but are not limited to, —F, —Cl, —Br, alkyl chlorides, alkyl bromides,alkyl iodides, alkyl sulfonates, alkyl benzenesulfonates, alkylp-toluenesulfonates, alkyl methanesulfonates, triflate, and any groupshaving a bisulfate, methyl sulfate, or sulfonate ion.

Typical protecting groups, reagents and solvents such as, but notlimited to, those listed below in table 1 have the followingabbreviations as used herein and in the claims. One skilled in the artwould understand that the compounds listed within each group may be usedinterchangeably; for instance, a compound listed under “reagents andsolvents” may be used as a protecting group, and so on. Further, oneskilled in the art would know other possible protecting groups, reagentsand solvents; these are intended to be within the scope of thisinvention.

TABLE 1 Protecting Groups Ada Adamantane acetyl Alloc AllyloxycarbonylAllyl Allyl ester Boc tert-butyloxycarbonyl Bzl Benzyl CbzBenzyloxycarbonyl Fmoc Fluorenylmethyloxycarbonyl OBzl Benzyl ester OEtEthyl ester OMe Methyl ester Tos (Tosyl) p-Toluenesulfonyl TrtTriphenylmethyl Reagents and Solvents ACN Acetonitrile AcOH Acetic acidAc.sub.2 O Acetic acid anhydride AdacOH Adamantane acetic acid AIBN2,2-azobisisobutyronitrile Alloc-Cl Allyloxycarbonyl chloride BHT2,6-di-tert-butyl-4-methylphenol Boc.sub.2 O Di-tert butyl dicarbonateCDI 1,1′-carbonyldiimidazole DIEA Diisopropylethylamine DIPEAN,N-diisopropylethylamine DMA Dimethylacetamide DMFN,N-dimethylformamide DMSO Dimethyl sulfoxide EDTAethylenediaminetetraacetic acid Et.sub.3 N Triethylamine EtOAc Ethylacetate FDH formate dehydrogenase FmocOSu 9-fluorenylmethyloxy carbonylN-hydroxysuccinimide ester HATU N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridiylmethylene]- N-methylmethanaminium hexafluorophosphate N-oxideHOBT 1-Hydroxybenzotriazole HF Hydrofluoric acid LDH lactatedehydrogenase LiHMDS Lithium bistrimethylsilylamide MeOH Methanol Mes(Mesyl) Methanesulfonyl MTBE t-butyl methyl ether NAD Nicotinamideadenine dinucleotide NADH Hydrogen-peroxide oxidoreductase NaHMDS Sodiumbistrimethylsilylamide NMP 1-methyl-2-pyrrolidinone nin. Ninhydrini-PrOH Iso-propanol Pip Piperidine PPL Lipase pTSA p-toluensulfonic acidmonohydrate Pyr Pyridine TEA Triethylamine TET triethylenetetraamine TFATrifluoroacetic acid THF Tetrahydrofuran Triflate (Tf)Trifluoromethanesulfonyl

The term “suitable organic moiety” is intended to mean any organicmoiety recognizable, such as by routine testing, to those skilled in theart as not adversely affecting the inhibitory activity of the inventivecompounds. Illustrative examples of suitable organic moieties include,but are not limited to, hydroxyl groups, alkyl groups, oxo groups,cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroarylgroups, acyl groups, sulfonyl groups, mercapto groups, alkylthio groups,alkoxy groups, carboxy groups, amino groups, alkylamino groups,dialkylamino groups, carbamoyl groups, arylthio groups, heteroarylthiogroups, and the like.

The term “substituent” or “suitable substituent” is intended to mean anysuitable substituent that may be recognized or selected, such as throughroutine testing, by those skilled in the art. Illustrative examples ofsuitable substituents include hydroxy groups, halogens, oxo groups,alkyl groups, acyl groups, sulfonyl groups, mercapto groups, alkylthiogroups, alkyloxy groups, cycloalkyl groups, heterocycloalkyl groups,aryl groups, heteroaryl groups, carboxy groups, amino groups, alkylaminogroups, dialkylamino groups, carbamoyl groups, aryloxy groups,heteroaryloxy groups, arylthio groups, heteroarylthio groups, and thelike.

The term “optionally substituted” is intended to expressly indicate thatthe specified group is unsubstituted or substituted by one or moresuitable substituents, unless the optional substituents are expresslyspecified, in which case the term indicates that the group isunsubstituted or substituted with the specified substituents. As definedabove, various groups may be unsubstituted or substituted (i.e., theyare optionally substituted) unless indicated otherwise herein (e.g., byindicating that the specified group is unsubstituted).

A “prodrug” is intended to mean a compound that is converted underphysiological conditions or by solvolysis or metabolically to aspecified compound that is pharmaceutically active.

A “pharmaceutically active metabolite” is intended to mean apharmacologically active product produced through metabolism in the bodyof a specified compound.

A “solvate” is intended to mean a pharmaceutically acceptable solvateform of a specified compound that retains the biological effectivenessof such compound. Examples of solvates include compounds of theinvention in combination with water, isopropanol, ethanol, methanol,DMSO, ethyl acetate, acetic acid, or ethanolamine.

A “pharmaceutically acceptable salt” is intended to mean a salt thatretains the biological effectiveness of the free acids and bases of thespecified compound and that is not biologically or otherwiseundesirable. Examples of pharmaceutically acceptable salts includesulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates,monohydrogenphosphates, dihydrogenphosphates, metaphosphates,pyrophaosphates, chlorides, bromides, iodides, acetates, propionates,decanoates, caprylates, acrylates, formates, isobutyrates, caproates,heptanoates, propiolates, oxalates, malonates, succinates, suberates,sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates,benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates,hydroxybenzoates, methoxybenzoates, phthalates, sulfonates,xylenesulfonates, phylacetates, phenylpropionates, phylbutyrates,citrates, lactates, γ-hydroxybutyrates, glycollates, tartrates,methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates,naphthalene-2-sulfonates, and mandelates.

The present invention further provides synthetic methods that arecomprised of one of the synthetic steps set forth in the presentdisclosure. A synthetic method is comprised of a synthetic step when thesynthetic step is at least part of the final synthetic method. In such afashion, the synthetic method can be only the synthetic step or haveadditional synthetic steps that may be associated with it. Such asynthetic method can have a few additional synthetic steps or can havenumerous additional synthetic steps.

If the antipicornaviral agent of formula I formed from the process ofthe present invention is a base, a desired salt may be prepared by anysuitable method known to the art, including treatment of the free basewith an inorganic acid, such as hydrochloric acid; hydrobromic acid;sulfuric acid; nitric acid; phosphoric acid; and the like, or with anorganic acid, such as acetic acid; maleic acid; succinic acid; mandelicacid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolicacid; salicylic acid; pyranosidyl acid, such as glucuronic acid orgalacturonic acid; alpha-hydroxy acid, such as citric acid or tartaricacid; amino acid, such as aspartic acid or glutamic acid; aromatic acid,such as benzoic acid or cinnamic acid; sulfonic acid, such asp-toluenesulfonic acid or ethanesulfonic acid; or the like.

If the antipicornaviral agent of formula I formed from the process ofthe present invention is an acid, a desired salt may be prepared by anysuitable method known to the art, including treatment of the free acidwith an inorganic or organic base, such as an amine (primary, secondary,or tertiary); an alkali metal or alkaline earth metal hydroxide; or thelike. Illustrative examples of suitable salts include organic saltsderived from amino acids such as glycine and arginine; ammonia; primary,secondary, and tertiary amines; and cyclic amines, such as piperidine,morpholine, and piperazine; as well as inorganic salts derived fromsodium, calcium, potassium, magnesium, manganese, iron, copper, zinc,aluminum, and lithium.

In the case of compounds, salts, or solvates that are solids, it isunderstood by those skilled in the art that the compounds of formula Iand the intermediates used in the process of the present invention,salts, and solvates thereof, may exist in different crystal forms, allof which are intended to be within the scope of the present inventionand specified formulas.

The antipicornaviral agents of formula I, and the intermediates used inthe process of the present invention, may exist as single stereoisomers,racemates, and/or mixtures of enantiometers and/or diastereomers. Allsuch single stereoisomers, racemates, and mixtures thereof are intendedto be within the broad scope of the present invention. Preferably,however, the intermediate compounds used in the process of the presentinvention are used in optically pure form.

As generally understood by those skilled in the art, an optically purecompound is one that is enantiomerically pure. As used herein, the term“optically pure” is intended to mean a compound comprising at least asufficient amount of a single enantiomer to yield a compound having thedesired pharmacological activity. Preferably, “optically pure” isintended to mean a compound that comprises at least 90% of a singleisomer (80% enantiomeric excess (hereinafter “e.e.”)), more preferablyat least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.),and most preferably at least 99% (98% e.e.) Preferably, theantipicornaviral agents of formula I formed from the process of thepresent invention are optically pure.

The present invention relates to a process of preparing antipicornaviralagents of formula I:

wherein

R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group;

R₂ and R₃ are each independently H;

where n is an integer from 0 to 5, A₁ is CH or N, A₂ and each A₃ areindependently selected from C(R₄₁)(R₄₁), N(R₄₁), S, S(O), S(O)_(2,) andO, and A₄ is NH or NR₄₁, where each R_(41,) is independently H or loweralkyl, provided that no more than two heteroatoms occur consecutively inthe above-depicted ring formed by A₁, A₂, (A₃),_(n), A₄ and C═O, and atleast one of R₂ and R₃ is

R₄ is

R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, or a heteroaryl group;

R₇ and R₈ are each independently H, an alkyl group, a cycloalkyl group,a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR₁₇,—SR₁₇, —NR₁₇R₁₈, —NR₁₉NR₁₇R₁₈, or —NR₁₇OR₁₈, where R₁₇, R,₁₈, and Rl₁₉are each independently H, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, or an acylgroup, provided that at least one of R₇ and R₈ is an alkyl group, anaryl group, a heteroaryl group, —OR₁₇, —SR₁₇, —NR₁₇R₁₈—NR₁₉NR₁₇R₁₈, or—NR₁₇OR₁₈; R₉ is a five-membered heterocycle having from one to threeheteroatoms selected from O, N, and S; and

Z and Z₁ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group,—C(O)R₂₁, —CO₂R₂₁, CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁,—C(S)NR₂₁R₂₂, —NO₂, —SOR₂₁, —SO₂R₂₁, —SO₂NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂),—SONR₂₁, —SO₃,R₂₁, —PO(OR₂₁)₂, —PO(R₂₁)(R₂₂), —PO(NR₂₁R₂₂)(OR₂₃),—PO(NR21R₂₂)(NR₂₃R₂₄), —C(O)NR₂₁NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁,R₂₂, R₂₃, and R₂₄ are each independently H, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group, anacyl group, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃,and R₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H;

or Z₁ and R₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z₁ and R₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group;

or Z and Z₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z and Z₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group.

The present invention discloses that a compound of formula I may beprepared by subjecting a compound of formula II and a compound offormula III to a amide-forming reaction:

The amide-forming reaction may be achieved by any suitable method,reagents and reaction conditions. Preferably, any one of the methodsdisclosed in the '354 application is utilized. For example, a compoundof formula II may be reacted with a compound of formula III in thepresence of HATU, DIPEA, CH₃CN and H₂O to yield desired compound offormula I. Any suitable purification method may be used to furtherpurify the compound of formula I.

More preferably, the compound of formula I is prepared by anamide-forming reaction comprising the steps of:

(a) reacting the compound of formula II with a compound of formula IIIAin the presence of N-methylmorpholine to form a reaction mixture; and

(b) adding a compound of formula Lv-X to the reaction mixture to form acompound of formula I, wherein X is any suitable halide.

Preferably, the method for preparing the compound of formula I utilizingthe more preferable amide-forming reaction utilizes some or all of thereagents and reaction conditions disclosed below. Thus, preferably, thecompound of formula II and the compound of formula IIIA in DMF arecombined in any suitable container. The suitable container is preferablya single neck flask which is then covered with any suitable septum andcovered with a temperature probe. Nitrogen gas is used to purge out thesuitable container before N-methylmorpholine is added to the reactionmixture. More preferably, the N-methylmorpholine is added via a syringein one single portion and the reaction mixture cooled to about between−5° C. and 5° C. More preferably, the reaction mixture is cooled toabout 0° C. A solution of the compound of formula Lv-X is then added tothe reaction mixture. More preferably, the solution of the compound offormula Lv-X is a solution of the compound of formula Lv-X in DMF. Evenmore preferably, the compound of formula Lv-X is CDMT. The solution ofthe compound of formula Lv-X is added to the reaction mixture by anysuitable method so as to maintain the reaction mixture at a constanttemperature. For example, the solution of the compound of formula Lv-Xmay be added to the reaction mixture dropwise utilizing a syringe. Uponcompletion of the addition of the solution of the compound of formulaLv-X, the reaction mixture is allowed to warm to about room temperature.The progress of the reaction may be followed by monitoring thedisappearance of the compound of formula II by thin layer chromatography(hereinafter “TLC”). When the reaction is at least substantiallycomplete, the compound of formula I may be precipitated out of solutionto form a slurry by slowly adding water to the reaction mixture. Thecompound of formula I may then be removed from the slurry by anysuitable means known to one of ordinary skill in the art. For example,the compound of formula I may be removed from the slurry by filtration.Any suitable purification method known to one of ordinary skill in theart may be used to purify the compound of formula I. More preferably,the compound of formula I is purified by recrystalization.

The present invention also discloses two alternate processes for thesynthesis of the compound of formula III and acid addition saltsthereof. Of these two routes, the second process is currently preferredbecause it offers greater cost-effectiveness at a commercial scale.

The first of these two processes is for the preparation of a compound offormula IV and its acid addition salts from a compound of formula V.

One of ordinary skill will recognize that the compounds of formula IVare a subgenus to those of formula III.

The compound of formula V may be prepared from commercially availableN-Boc L glutanic acid γ-benzyl ester. Any suitable method may be used toprepare the compound of formula V. Preferably, the method disclosed inU.S. patent application Ser. No. 08/991,739 is used. U.S. patentapplication Ser. No. 08/991,739 is herein incorporated by reference inits entirety.

The process of the present invention comprises the steps of:

(a) cyanomethylation of the compound of formula V usingbis(trimethysily)amide and bromoacetonitrile to yield a compound offormula VI;

(b) the reduction, cyclization, and deprotection of the compound offormula VI in that respective order to yield a compound of formula VII;and

(c) the oxidation and olefination of the compound of formula VII byreacting the compound with a SO₃-pyridine complex to yield a reactionmixture and reacting the reaction mixture with a phosphorane of formulaVIII.

According to the present invention, and as disclosed above, thepreparation of the compound of formula V from N-Boc glutanic acidγ-benzyl ester may be carried out by any suitable method known in theart.

Further, the cyanomethylation of the compound of formula V may becarried out using any suitable method, reagents and reaction conditions.Preferably, the method disclosed below and the use of all or some of thereagents and reaction conditions are used. Thus, it is preferable, thatthe compound of formula V be added dropwise to a stirring solution ofNaHMDS in THF at −70° C. in a nitrogen atmosphere over a period of atleast about 5 hours before being mixed with bromoacetonitrile.

This cyanomethylation of the compound of formula V usingbis(trimethylsilyl)amide and bromoacetonitrile affords the compound offormula VI along with its epimer in a 5:1 ratio. However, the compoundmay be purified by any suitable method. Preferably, the compound offormula VI is purified by filtration and chromatography, followed bytitration. Under these preferred conditions, a 60% overall yield of thecompound of formula VI is attainable having >99% diastereomeric purity.

The three step reduction, cyclization, and deprotection reaction of step(b) to convert the compound of formula VI to the compound of formula VIImay be carried out using any suitable reagents and reaction conditions.Preferably, the method disclosed below, using all or some of thereagents and reaction conditions are used. Therefore, preferably, thecompound of formula VI is reduced by adding a solution of cobalt (II)chloride hexahydrate to a solution of the compound of formula VI intetrahydrofuran in methanol. The resulting solution is cooled to about0° C. before sodium borohydride is added in portions over a period of atleast about 7 hours. Then, p-toluensulfonic acid monohydrate is added tothe solution of crude material in methanol and allowed to react for atleast about 18 hours at an ambient temperature. After removal of thesolvent, the residue is dissolved in ethyl acetate and washed. Anysuitable washing agent may be used. More preferably, the washing agentis saturated sodium bicarbonate. The crude product is then charged witha solution of methanol in water. More preferably, a 2.5% methanolsolution is used. The crude product may be removed from solution by anysuitable method. For example, the crude product may be removed byfiltration and the filtrate concentrated on a rotary evaporator. Theproduct is then dissolved in ethyl acetate, dried, filtered andconcentrated to the crude compound of formula VII. More preferably, theproduct is dried over MgSO₄. The crude compound of formula VII may befurther purified by any suitable purification process. More preferably,the crude compound of formula VII is purified through a titrationprocess using 1:1 ethyl acetate and hexanes.

An overall yield of at least about 95% pure compound of formula VII isattainable if the preferred three step reduction, cyclization, anddeprotection reaction disclosed above is used.

Any suitable method, reagents and reaction conditions may be used in thesubsequent oxidation and olefination employing a SO₃-pyridine complexand the phosphorane of formula VIII to yield the compound of formula IV.Preferably, the method disclosed below and all or some of the reagentsand reaction conditions are used. Accordingly, preferably, triethylamineis added to a solution of the compound of formula VIII andmethylsulfoxide. The resulting solution is cooled to about 5° C.,followed by the addition of a sulfur trioxide-pyridine complex. Thereaction is stirred at about 5° C. for at least about 15 minutes. Afterremoving the source used to cool the solution to about 5° C., thereaction is stirred for at least about an additional 1 hour.(Carboethoxymethylenetriphenyl)-phosphorane is then added and thereaction mixture stirred at ambient temperature for at least about 3hours. Then, the reaction is quenched and extracted with ethyl acetate.More preferably, the reaction is quenched by the addition of saturatedbrine. The combined organic phases are then washed, dried, filtered andconcentrated to afford crude compound of formula IV. More preferably,the combined organic phases are washed with saturated brine and driedover MgSO₄.

The compound of formula IV may be purified by any suitable method.Preferably, chromatography purification and titration techniques areused. If the preferable purification technique is used, yields rangingfrom 55% to 60% are attainable.

The second process for preparing the compound of formula IV, and itsacid addition salts, disclosed by the present invention comprises thesteps of:

(a) the dianionic alkylation of a compound of formula IX usingbromoacetonitrile to yield a compound of formula X;

(b) hydrogenation of the compound of formula X to yield an amine offormula XI;

(c) reacting the amine of formula XI with ET₃N to yield a lactam esterof formula XII;

(d) the reduction of the lactam ester of formula XII through a suitablereduction procedure to yield a compound of formula XIII;

(e) the oxidation and olefination of the compound of formula XIII toyield a compound of formula XIV by reacting it with a compound offormula XV; and

(f) converting the compound of formula XIV to the compound of formulaIV.

Further, one of ordinary skill in the art will realize that the abovedisclosed method may be used to prepare the compound of formula XIV.Specifically, steps (a)-(e) disclose a process for preparing thecompound of formula XIV.

The compound of formula IX may be prepared by any suitable method knownin the art. For example, N-Boc L-(+)-glutamic acid dimethyl ester may beprepared from commercially available L-glutamic acid dimethyl esterhydrochloride or commercially available L-glutamic acid 5-methyl esteraccording to literature procedures. See for example, Shimamoto et al, J.Org. Chem. 1991, 56, 4167 and Duralski et al, Tetrahedron Lett. 1998,30, 3585. These references are herein incorporated by reference in theirentirety.

Preferably, the dianionic alkylation reaction is performed using themethod and all or some of the reagents and reaction conditions disclosedbelow. Therefore, preferably, the compound of formula IX is firstdissolved in THF to form a solution which is added dropwise to astirring solution of LiHMDS at −78° C. in an Argon atmosphere. Theresulting mixture is then stirred at about −78° C. for 2 hours beforefreshly distilled bromoacetonitrile is added dropwise over a period of 1hour. The reaction mixture is stirred at about −78° C. for additional 2hours. The reaction is then quenched. More preferably, the reaction isquenched by adding 0.5 M HCl and H₂O. The resulting aqueous layer isseparated and is extracted further with methyl tert-butyl ether. Thecombined organic extract is washed, dried and filtered. More preferably,the organic extract is washed with saturated NaHCO₃ and brine and driedover MgSO₄. The solvent is evaporated under reduced pressure.

The compound of formula IX may be hydrogenated to the amine of formulaXI by any suitable method known in the art. Preferably, thehydrogenation is performed in the presence of 5% Pd/C. More preferably,the hydrogenation reaction is performed in accordance with the method,using some or all of the reagents and reaction conditions disclosedbelow. According to this preferred hydrogenation method, the compound offormula IX is dissolved in HOAc and shaken with 5% Pd on C under H₂ gas,at 50 psi pressure, for 3 days. The mixture is then filtered overcelite. The filtrate may then be evaporated under reduced pressure andthe residue repeatedly evaporated from methyl tert-butyl ether.

The reaction of the amine of formula XI with Et₃N may be achieved usingany suitable conditions. Preferably, the method and all or some of thereagents and reaction conditions disclosed below are used. Accordingly,preferably, the amine of formula XI is dissolved in 1:1 MeOH/THF, beforeEt₃N is added to the solution. The resulting mixture is stirred at about45° C. for about 10 hours or until the starting material hasdisappeared. The presence of the starting material may be monitored by¹H NMR. After stripping off the solvent, methyl tert-butyl ether isadded. The precipitate is then filtered. 0.5 M HCl is added to thefiltrate diluted with H₂O. After splitting the phases, the aqueous phasemay be extracted with ethyl acetate. The combined organic phases arewashed, dried, filtered and concentrated. More preferably, the combinedorganic phases are washed with brine and dried over MgSO₄. The phasesmay be concentrated on a rotovapor. Flash chromatography furnishes thelactam ester of formula XII.

Any suitable reduction method may be used to convert the lactam ester offormula XII to the compound of formula XIII. Preferably, LiBH₄ is usedas the reducing agent. More preferably, the method, or any portionthereof, and any or all of the reagents and reaction conditionsdisclosed below are used. Thus, more preferably, LiBH₄ is added to astirring solution of the lactam ester of formula XII in THF. The LiBH₄is added in several portions at 0° C. in an Argon atmosphere. Thereaction mixture is stirred at 0° C. for 10 minutes, before beingallowed to warm to ambient temperature and stirred for an additional 2hours. Then, the reaction is quenched. Even more preferably, thereaction is quenched by the dropwise addition of 0.5 M HCl while coolingusing an ice bath. The solution is diluted with ethyl acetate and H₂O.After splitting the phases, the aqueous phase may be extracted withethyl acetate. The combined organic phases are washed, dried, filteredand concentrated. Even more preferably, the combined organic phases arewashed with brine and dried over MgSO₄. The phases may be concentratedon a rotovapor. Flash chromatography furnishes the compound of formulaXII.

Any suitable oxidation and olefination method may be used to prepare thecompound of formula XIV from the compound of formula XIII. Preferably,the method, or any part thereof, and all or some of the reagents andreaction conditions described below are used. Thus, in accordance withthe present invention, benzoic acid,(carboethoxymethylenetriphenyl)phosphorane and DMSO are added to asolution of the compound of formula XIII in CH₂Cl₂. Dess-Martinperiodinane is added to the solution in several portions, and thereaction mixture is then stirred for at least about 5 hours at ambienttemperature until the compound of formula XIII substantially disappears.The presence of the compound of formula XIII may be monitored by ¹H NMR.Saturated NaHCO₃ solution is added before the mixture is stirred for 30minutes to yield a precipitate. The precipitate is filtered prior to theorganic phase of the filtrate being separated, washed, and concentratedto yield the crude compound of formula XIV. More preferably, thefiltrate is washed with brine and concentrated on a rotovapor. Anysuitable method may be used to purify the crude compound of formula XIV.More preferably, the crude compound of formula XIV is purified by flashchromatography, then dissolved in ethyl acetate. Excess hexanes are thenadded gradually to the stirring solution to yield a precipitated. Theprecipitate is filtered and dried to afford the compound of formula XIV.More preferably, the precipitate is dried in a vacuum oven for at leastabout 12 hours.

The following examples are provided merely for illustrative purposes ofthe present invention and are not to be read as limiting the scope ofprotection of the present invention, as defined by the appended claims.

EXAMPLES

The following illustrates an example of the amide-forming reactionbetween two compounds falling within the scope of formulae II and III toprepare a compound falling within the scope of formula I. Specifically,this example, as depicted in Scheme 1 below, illustrates the reaction of1 with 2 to prepare the protease inhibitor AG7088.

The following examples disclose the preparation of compound 1 fallingwithin the scope of formula IV. The first example, as depicted in Scheme2 below, illustrates the use of the cyanomethylation route disclosedabove. The second example, depicted in Scheme 3 below, illustrates thesecond more preferable cost effective route for preparing the samecompound.

Preparation of 4 (Scheme 2)

A solution of3 (1.0 k, 2.34 mol, 1.0 equiv.) in THF (8.0 L) was addeddropwise to a stirring solution of NaHMDS in THF (1M in THF, 2.96 L,1.28 equiv.) at −70° C. in a nitrogen atmosphere over a period of 5hours. The resulting solution was stirred at −70° C. for 0.5 hours andfreshly distilled bromoacetonitrile (320 mL, 2.0 equiv.) was then addeddropwise over a period of 25 minutes. The reaction mixture was stirredat −70° C. for additional 1 hour until the disappearance of the startingmaterial 3. The reaction was quenched by addition of saturated ammoniumchloride solution (7.0 L), and extracted with methyl tert-butyl ether(24 L). The organic phase was washed with brine (3×6.0 L). The solventwas removed under reduce pressure to afford a dark brown oil (1.5 kg).This crude product was dissolved in methylene chloride (8.0 L) andpassed over a bed of silical gel (600 g) and activated carbon (250 g).After rinsing the cake with methylene chloride (4.0 L), the filtrate wasconcentrated on a rotary evaporator to afford a light brown oil (1,28Kg), which was then dissolved in ethyl acetate (2.5 L). To the resultingsolution, excess hexanes (14.5 L) were added under vigorous stirring anda white solid precipitated out in 30 minutes. The slurry was cooled withan ice-water bath and stirred for 4.5 hours, followed by filtration toafford 4 as a light brown solid (662 g, 60%): ¹H NMR (CDCl₃) δ1.46 (s, 3H), 1.49 (s, 9 H), 1.59 (s, 3 H), 1.75-1.95 (m, 1 H), 2.15-2.31 (m, 1H), 2.55-3.15 (m, 3 H), 3.36 (d,J=10.8 Hz, 1 H), 3.62-4.10 (m, 3 H),4.13-4.32 (m, 3 H), 4.70 (m, 1 H), 7.15-7.42 (m, 5 H).

Preparation of 6 (Scheme 3)

Compound 6 was prepared from L-glutamic acid dimethyl esterhydrochloride (commercially available from Lancaster) or L-glutamic acid5-methyl ester (commercially available from Aldrich) according toliterature procedures.

Preparation of 7 (Scheme 3)

A solution of N-Boc L-(+)-glutamic acid dimethyl ester (6, 10 g, 36.3mmol, 1 equiv.) in THF (100 mL) was added dropwise to a stirringsolution of LiHMDS (77 mL, 1M in THF, 77.0 mmol, 2.1 equiv.) at −78° C.in an Ar atmosphere. The resulting dark mixture was stirred at −78° C.for 2 hours, and then freshly distilled bromoacetonitrile (13.1 g, 109.0mmol, 3 equiv.) was added dropwise over a period of 1 hour. The reactionmixture was stirred at −78° C. for additional 2 hours and thedisappearance of the starting material (6) was confirmed by TLCanalysis. The reaction was quenched by addition of HCl (120 mL, 0.5 M)and H₂O (200 mL). The layers were separated, and the aqueous layer wasfurther extracted with methyl tert-butyl ether (3×200 mL). The combinedorganic extract was washed with saturated NaHCO₃ (2×250 mL), brine(2×250 mL), dried over MgSO₄ and filtered. The solvent was evaporatedunder reduce pressure to give a brown oil (15.2 g). Flash chromatographyover silica gel (3:1 hexanes/ethyl acetate) afforded a colorless oil (7,6.67 g, 10.8 mmol, 58%): ¹H NMR (CDCl₃) δ1.46 (s, 9 H), 2.12-2.24 (m, 2H), 2.77-2.82 (m, 2 H), 2.85-2.91 (m, 1 H), 3.78 (s, 3 H), 3.79 (s, 3H), 4.32-4.49 (m, 1H), 5.13 (d,J=6.0 Hz, 1 H); ¹³C NMR (CDC13) δ19.4,28.6, 34.3, 38.6, 49.8, 53.1, 80.9, 117.5, 155.9, 172.4, 172.8; HRMS m/z314.1481 (calculated for C₁₂H₂₂N₂O₄, 314.1486).

Preparation of 8 (Scheme 3)

Compound 7 (4.60 g, 14.6 mmol) was dissolved in HOAc (120 mL) and shakenwith 5% Pd on C (20 g) under H₂ gas (50 psi) for 3 days. The mixture wasfiltered over Celite. The filtrate was evaporated under reduced pressureand the residue was repeatedly evaporated from methyl tert-butyl etherto yield a light pink solid (8, 8.32 g), which was used directly in thenext step. ¹H NMR (CD₃OD) δ1.47 (s, 9 H), 1.85-2.10 (m, 4 H), 2.60-2.62(m, 1 H), 2.92-2.96 (m, 2 H), 3.74 (s, 3 H), 3.77 (s, 3 H), 4.22-4.26(m, 1 H); Note: Experiments have demonstrated that less 5% Pd on C candrive the reaction to completion, i.e., 1 g of 5% Pd on C was efficientfor the reduction of 2 g of 7.

Preparation of 9 (Scheme 3)

Crude 8 was dissolved in 1:1 MeOH/THF (40 mL) and Et₃N (7 mL) was addedto the solution. The resulting mixture was stirred at 45° C. for 10hours until the disappearance of the starting material monitored by ¹HNMR. After stripping off the solvent on a rotovapor, methyl tert-butylether (200 mL) was added and a white solid precipitated out. The solidprecipitate was removed by filtration. The filtrate was diluted with 200mL of H₂O followed by addition of 0.5 M HCl (5 mL). The phases weresplit, and the aqueous phase was extracted with ethyl acetate (4-200mL). The combined organic phases were washed with brine (2-700 mL),dried over MgSO₄, filtered and concentrated on a rotovapor to give alight brown oil. Flash chromatography furnished a white solid (9, 2.5 g,8.74 mmol, 60%): ¹H NMR (CDCl₃) δ1.37 (s, 9 H), 1.75-1.80 (m, 2 H),2.04-2.09 (m, 1 H), 2.39-2.42 (m, 2 H), 3.25-3.29 (m, 2 H), 3.67 (s, 3H), 4.23-4.26 (m, 1 H), 5.47 (d,J=8.0 Hz, 1 H), 6.29 (s, 1 H); ¹³C NMR(CDCl3) δ28.5. 28.6, 34.5, 38.5, 40.7, 52.7, 52.8, 80.3, 156.1, 173.3,180.0; HRMS m/z 286.1564 (calculated for C₁₃H₂₂N₂O₅, 286.1587).

Preparation of 5 from 4 (Scheme 2)

To a solution of 4 (400 g, 0.85 mol, 1 equiv.) in tetrahydrofuran (3.0L) was added a solution of cobalt (II) chloride hexahydrate (200 g, 0.85mol, 1 equiv.) in methanol (3.0 L). The resulting solution was cooled to0° C. and sodium borohydride (130 g, 3.51 mol, 4.4 equiv.) was added inportions over a period of 7 hours. The reaction mixture was allowed towarm to ambient temperature and stirred for 20 hours while beingmonitored by TLC for the disappearance of the starting material (4). Thereaction was cooled to 0° C. and quenched by addition of 1.0 M HCl (14L) and ethyl acetate (12 L). The phases were separated and the aqueousphase was charged with 2.0 kg of sodium chloride and 4.0 L of ethylacetate. The phases were separated, and the organic phases werecombined, washed with brine (1×3.0 L), concentrated on a rotaryevaporator to afford a crude material (440 g), which was used directlyin the following hydrolysis reaction. To a solution of the crudematerial (440 g, 1 equiv.) in methanol (800 mL) was addedp-toluensulfonic acid monohydrate (4.0 g, 0.015 equiv.). The reactionwas stirred at ambient temperature overnight. The solvent was removed ona rotary evaporator and the residue was dissolved in ethyl acetatc (2.0L), washed with saturated sodium bicarbonate (2×100 mL). The combinedaqueous phases were extracted with ethyl acetate (2×200 mL). All theorganic phases were combined, concentrated on a rotary evaporator toafford 275 g of the crude product, which was charged with a solution of2.5% methanol (20 mL) in water (780 mL) and stirred at ambienttemperature overnight. The granular solid (chiral auxiliary) was removedby filtration and the filtrate was concentrated on a rotary evaporator.The residue was dissolved in ethyl acetate (1.5 L), dried over MgSO₄,filtered and concentrated to afford a viscous oil. The oil was furtherpurified through a titration process using 1:1 ethyl acetate (1 L) andhexanes (1 L) to afford 5 as a white solid (104 g, 47% overall yieldfrom 4).

Preparation of 5 from 9 (Scheme 3)

To a stirring solution of 9 (1.75 g, 6.10 mmol) in THF (40 mL) was addedLiBH₄ (270 mg, 12.2 mmol, 2 equiv.) in several portions at 0° C. in anArgon atmosphere. The reaction mixture was stirred at 0° C. for 10minutes, then allowed to warm to ambient temperature and stirred foradditional 2 hours. The reaction was quenched by the dropwise additionof 0.5 M HCl (24 mL) with cooling in an ice bath (Note: formation ofgases was observed). The solution was diluted with ethyl acetate (100mL) and H₂O (50 mL). The phases were split, and the aqueous layer wasextracted with ethyl acetate (6×150 mL). The combined organic phaseswere dried over MgSO₄, filtered and concentrated on rotovapor to give alight brown oil. Flash chromatography afforded a white solid (5, 1.308g, 5.06 mmol, 83%): ¹H NMR (CDCl₃) δ1.46 (s, 9 H), 1.61-1.67 (m, 1 H),1.82-1.91 (m, 1 H), 1.94-2,00 (m, 1 H), 2.43-2.48 (m, 1 H), 2.49-2.55(m, 1 H), 3.32-3.34 (m, 3 H), 3.58-3.66 (m, 2 H) 3.68-3.79 (m, 2 H),5.47 (d,J=7.0 Hz, 1 H), 6.24 (s, 1 H); ¹³C NMR (CDCl₃) δ28.8, 32.9,38.4, 40.8, 51.5, 66.3, 79.8, 157.0, 181.3; HRMS m/z 258.1652(calculated for C₁₃H₂₂N₂O₅, 258.1650).

Preparation of 1 from 5

Procedure A (Scheme 2)

To a solution of 5 (50.0 g, 0.184 mol, 1 equiv.) methylsulfoxide (500mL) was added triethylamine (116 mL). The resulting solution was cooledto 5° C. with an ice bath, followed by addition of sulfurtrioxide-pyridine complex (132 g). The reaction was stirred at thattemperature for 15 min. The cold bath was removed and the reaction wasstirred for additional 1 hour.(Carboethoxymethylenetriphenyl)-phosphorane (112 g) was added in one lotand the reaction was stirred at ambient temperature for 3 hours. Thereaction was quenched by addition of saturated brine (3.0 L), extractedwith ethyl acetate (3×1.5 L). The combined organic phases were washedwith saturated brine (3×5 L), dried over MgSO₄, filtered andconcentrated to afford a dark red oil. The oil was purified through achromatography, followed by a titration process using ethyl acetate (60mL) and excess of hexanes (240 mL). 1 was obtained as a white solid(36.0 g, 60%).

Procedure B (Scheme 3)

To a solution of 5 (1.0 g, 3.87 mmol, 1 equiv.) in CH₂Cl₂ (80 mL) wasadded benzoic acid (1.89 g, 15.5 mmol., 4 equiv.),(carboethoxymethylenetriphenyl)phosphorane (5.39g, 15.5 mmol, 4 equiv.)and DMSO (4.8 mL). Dess-Martin periodinane (4.1 g, 9.17 mmol, 2.5equiv.) was added in several portions to the solution, and the reactionmixture was then stirred for 5 hours at ambient temperature until thedisappearance of the starting material 5. Saturated NaHCO₃ solution wasadded, and the mixture was stirred for 30 minutes. A white solidprecipitated out, which was then filtered off. The organic phase of thefiltrate was separated, washed with brine (250 mL), and concentrated onrotovapor to give a brown oil, which was purified by flashchromatography to produce a light brown foam (0.956 g). The foam wasdissolved in ethyl acetate (3 mL). Excess hexanes (12 mL) was addedgradually to the stirring solution and a white solid precipitated out.The solid was filtered and dried in vacuum oven overnight to afford 1(0.69 g, 2.11 mmol, 55%). Chiral HPLC: 97% pure, 98% de and 100% Eisomer; ¹H NMR (CDCl₃) δ1.22 (t, J=7.2 Hz, 3 H), 1.38 (s, 9 H),1.53-1.58 (m, 1 H), 1.66-1.84 (m, 1 H), 1.85-2.00 (m, 1 H), 2.30-2.50(m, 2 H), 3.20-3.37 (m, 2H), 4.13 (q,J=7.2 Hz, 2 H), 4.20-4.35 (m, 1 H),5.13 (d,J=7.5 Hz, 1 H), 5.68 (s, 1 H), 5.90 (dd,J=1.8, 15.6 Hz, 1 H),6.80 (dd, J=5.1, 15.6 Hz, 1 H); HRMS m/z 326.1846 (calculated forC₁₆H₂₆N₂O₆, 326.1840).

Preparation of AG7088 from 1 and 2 (Scheme 1)

751 mg of compound 1 was dissolved in DCM (10 mL/g of 1) in a singleneck round bottom flask and cover with a septum. The flask was thenpurged with nitrogen followed by the addition of 1.4 mL TFA via syringewhile the solution was being stirred. The progress of the reaction wasmonitored by TLC using 5% MeOH in DCM until after about 4 hours thestarting material disappeared. The solvent and excess TFA were removedunder vacuum at pressure of <50 mTorr @ 45° C. The product, compound 1A,was used immediately in the step set forth below.

Compounds 1A and 2 were dissolved in DMF (7 mL/g of 2) in a single neckflask covered with a septum and fitted with a temperature probe. Theflask was purged with nitrogen. The resulting solution was divided intotwo portions. In a first portion was added 1.6 mL n-methylmorpholine viasyringe and cooled to 0° C.±5° C. In a second portion of the solution281 mg CDMT was dissolved. This CDMT solution was then added dropwisevia syringe to the first portion of the solution, maintaining thereaction temperature of 0° C.±5° C. The resulting reaction mixture wasthen allowed to warm to room temperature. The reaction was monitored forabout 1 hour by TLC (7:3:1 hexanes:EtOAc:IPA) until the compound 2disappeared. Once the reaction was complete the product AG7088 wasprecipitated out of solution by the slow addition of water to reactionmixture. The resulting slurry was filtered to obtain a yield of >85%white granular crystals of compound AG7088 having a purity of >97%. Theproduct may then be recrystallized by dissolving it in hot MeOH:EtOAc1:1 followed by slow addition of hexanes (2 vols.)

It is to be understood that the foregoing description is exemplary andexplanatory in nature, and is intended to illustrate the invention andits preferred embodiments. Through routine experimentation, the artisanwill recognize apparent modifications and variations that may be madewithout departing from the spirit of the invention. Thus, the inventionis intended to be defined not by the above description, but by thefollowing claims and their equivalents.

What is claimed is:
 1. A process useful in synthesizing antipicornaviralcompounds, comprising: (a) performing cyanomethylation of a compound offormula V using bis(trimethysily)amide and bromoacetonitrile to yield acompound of formula VI;

(b) performing reduction, then cyclization, and then deprotection of thecompound of formula VI to yield a compound of formula VII; and

(c) performing oxidation and olefination of the compound of formula VIlby reacting the compound of formula VII with a SO₃-pyridine complex toyield a

 reaction mixture and reacting the reaction mixture with a compound forformula VIII to form a compound of formula IV: (d) deprotecting thecompound of formula IV to yield a compound of formula IVA:

(e) subjecting a compound of formula II and the compound of formula IVAto an amide-forming reaction to yield a compound of formula IA:

wherein each R₄₁ is independently H or lower alkyl, R₄ is

R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, or a heteroaryl group;and Z and Z₁ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group,—C(O)R₂₁, —CO₂R₂₁, CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁,—C(S)NR₂₁R₂₂, —NO₂, —SOR₂₁, —SO₂R₂₁, wherein R₁ is H, F, an alkyl group,OH, SH, or an O-alkyl group; wherein each R₄₁ is independently H orlower alkyl; wherein X is any suitable protecting group for nitrogen andwherein Z and Z₁ are each independently H, F, an alkyl group, acycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroarylgroup, —C(O)R₂₁, —CO₂R₂₁, CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁,—C(S)NR₂₁R₂₂, —NO₂, —SOR₂₁, —SO₂R₂₁, —SO₂NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂),—SONR₂₁, —SO₃R₂₁, —PO(OR₂₁)₂, —PO(R₂₁)(R₂₂), —PO(NR₂₁R₂₂)(OR₂₃),—PO(NR₂₁R₂₂)(NR₂₃R₂₄), —C(O)NR₂₁NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁,R₂₂, R₂₃, and R₂₄ are each independently H, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, a heteroaryl group, anacyl group, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃,and R₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H; or Z₁ andR₁, together with the atoms to which they are bonded, form a cycloalkylor heterocycloalkyl group, where Z₁ and R₁ are as defined above exceptfor moieties that cannot form the cycloalkyl or heterocycloalkyl group;or Z and Z₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z and Z₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group.
 2. The process of claim 1, wherein the compoundof formula V is prepared from N-Boc L glutanic acid γ-benzyl ester. 3.The process of claim 1, wherein X is a Boc group.
 4. The process ofclaim 1, wherein R₄₁ is H.
 5. The process of claim 1, wherein Z is H. 6.The process of claim 1, wherein Z₁ is —COOEt.
 7. A process useful insynthesizing antipicornaviral compounds according to claim 1, furthercomprising the steps of: —SO₂NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂), —SONR₂₁, —SO₃R₂₁,—PO(OR₂₁)₂, —PO(R₂₁)(R₂₂), —PO(NR₂₁R₂₂)(OR₂₃), —PO(NR₂₁R₂₂)(NR₂₃R₂₄),—C(O)NR₂₁ NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁, R₂₂, R₂₃, and R₂₄ areeach independently H, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, an acylgroup, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃, andR₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H; or Z₁ andR₁, together with the atoms to which they are bonded, form a cycloalkylor heterocycloalkyl group, where Z₁ and R₁ are as defined above exceptfor moieties that cannot form the cycloalkyl or heterocycloalkyl group;or Z and Z₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z and Z₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group.
 8. The process of claim 7, wherein X is a Bocgroup.
 9. The process of claim 7, wherein compound IV is


10. The process of claim 7, wherein the compound of formula II is


11. The process of claim 7, wherein the compound of formula IVA is


12. The process according to claim 7, wherein the compound of formula IAis


13. A process useful in synthesizing antipicornaviral compounds,comprising: (a) performing dianionic alkylation of a compound of formulaIX using bromoacetonitrile to prepare a compound of formula X;

(b) performing hydrogenation of the compound of formula X to yield anamine of formula XI;

(c) reacting the compound of formula XI with Et₃N to yield a lactamester of formula XII;

(d) performing reduction of the lactam ester of formula XII to yield acompound of formula XIII:

(e) performing oxidation and olefination of the compound of formula XIIIto yield a compound of formula XIV by reacting it with a compound offormula XV:

 wherein each R₄₁ is independently H or lower alkyl; Z and Z₁ are eachindependently H, F, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, —C(O)R₂₁,—CO₂R₂₁, CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁, —C(S)NR₂₁R₂₂, —NO₂,—SOR₂₁, —SO₂R₂₁, —SO₂NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂), —SONR₂₁, —SO₃R₂₁,—PO(OR₂₁)₂, —PO(R₂₁)(R₂₂), —PO(NR₂₁ R₂₂)(OR₂₃), —PO(NR₂₁R₂₂)(NR₂₃R₂₄),—C(O)NR₂₁NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁, R₂₂, R₂₃, and R₂₄ areeach independently H, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, an acylgroup, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃, andR₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H; or Z andZ₁, together with the atoms to which they are bonded, form a cycloalkylor heterocycloalkyl group, where Z and Z₁ are as defined above exceptfor moieties that cannot form the cycloalkyl or heterocycloalkyl group;and X is any suitable protecting group for nitrogen.
 14. The processuseful in synthesizing antipicornaviral compounds according to claim 13,further comprising: preparing a compound of formula IV by converting thecompound of formula XIV to yield the compound of formula IV:

wherein R₁ is H, F, an alkyl group, OH, SH, or an O-alkyl group.
 15. Theprocess useful in synthesizing antipicornaviral compounds according toclaim 14, further comprising: Step A: deprotecting the compound offormula IV to yield a compound of formula IVA:

Step B: subjecting a compound of formula II and the compound of formulaIVA to an amide-forming reaction to yield a compound of formula IA:

 wherein each R₄₁ is independently H or lower alkyl, R₄ is

R₅ and R₆ are each independently H, F, an alkyl group, a cycloalkylgroup, a heterocycloalkyl group, an aryl group, or a heteroaryl group; Zand Z₁ are each independently H, F, an alkyl group, a cycloalkyl group,a heterocycloalkyl group, an aryl group, a heteroaryl group, —C(O)R₂₁,—CO₂R₂₁), CN, —C(O)NR₂₁R₂₂, —C(O)NR₂₁OR₂₂, —C(S)R₂₁, —C(S)NR₂₁R₂₂, —NO₂,—SOR₂₁, —SO₂R₂₁, —SO₂NR₂₁R₂₂, —SO(NR₂₁)(OR₂₂), —SONR₂₁, —SO₃R₂₁,—PO(OR₂₁)₂, —PO(R₂₁)(R₂₂), —PO(NR₂₁R₂₂)(OR₂₃), —PO(NR₂₁R₂₂)(NR₂₃R₂₂),—C(O)NR₂₁NR₂₂R₂₃, or —C(S)NR₂₁NR₂₂R₂₃, where R₂₁, R₂₂, R₂₃, and R₂₄ areeach independently H, an alkyl group, a cycloalkyl group, aheterocycloalkyl group, an aryl group, a heteroaryl group, an acylgroup, or a thioacyl group, or where any of two of R₂₁, R₂₂, R₂₃, andR₂₄, together with the atom(s) to which they are bonded, form aheterocycloalkyl group, provided that Z and Z₁ are not both H; or Z₁ andR₁, together with the atoms to which they are bonded, form a cycloalkylor heterocycloalkyl group, where Z₁ and R₁ are as defined above exceptfor moieties that cannot form the cycloalkyl or heterocycloalkyl group;or Z and Z₁, together with the atoms to which they are bonded, form acycloalkyl or heterocycloalkyl group, where Z and Z₁ are as definedabove except for moieties that cannot form the cycloalkyl orheterocycloalkyl group.
 16. The process of claim 13, wherein X is a Bocgroup.
 17. The process of claim 13, wherein R₄₁ is H.
 18. The process ofclaim 13, wherein Z is H.
 19. The process of claim 13, wherein Z₁ is—COOEt.
 20. The process of claim 14, wherein R₁ is H.
 21. A processuseful for the synthesis of a compound of formula IA′, and acid additionsalts thereof:

comprising the steps of: Step A: preparing a compound of formula IV′:

 comprising: performing cyanomethylation of a compound of formula V′using bis(trimethysily)amide and bromoacetonitrile to yield a compoundof formula VI′;

performing reduction, then cyclization, and then deprotection of thecompound of formula VI′ to yield a compound of formula VII′; and

performing oxidation and olefination of the compound of formula VII byreacting the compound with a SO₃-pyridine complex before the resultingreaction mixture is reacted with Ph₃P═CHCO₂Et; Step B: deprotecting thecompound of formula IV to yield a compound of formula IVA′:

Step C: subjecting a compound of formula II′ and the compound of formulaformula IVA′ to an amide-forming reaction;


22. The process of claim 21, wherein the compound of formula V isprepared from N-Boc L glutanic acid γ-benzyl ester.
 23. A process usefulin synthesizing antipicornaviral compounds, comprising: (a) performingdianionic alkylation of a compound of formula IX′ usingbromoacetonitrile to prepare a compound of formula X′;

(b) performing hydrogenation of the compound of formula X′ to yield anamine of formula XI′;

(c) reacting the compound of formula XI′ with Et₃N to yield a lactamester of formula XII′;

(d) performing reduction of the lactam ester of formula XII′ to yield acompound of formula XIII′:

(e) performing oxidation and olefination of the compound of formulaXIII′ to yield a compound of formula XIV′ by reacting it withPh₃P═CHCO₂Et;


24. The process useful in synthesizing antipicornaviral compoundsaccording to claim 23, further comprising: converting the compound offormula XIV′ to the compound of formula IV′;


25. The process useful in synthesizing antipicornaviral compoundsaccording to claim 24, further comprising: Step A: deprotecting thecompound of formula IV′ to yield a compound of formula IVA′:

 and Step C: subjecting a compound of formula II′ and the compound offormula IVA′ to an amide-forming reaction;